Holen Sie sich die Stockscreener-App
3.31
2.36%
-0.08
Vorhandelsmarkt:
3.29
-0.02
-0.60%
Lexeo Therapeutics Inc Aktie (LXEO) Neueste Nachrichten
The week in pharma: action, reaction and insight – week to September 25, 2026 - The Pharma Letter
LXEO News | LEXEO THERAPEUTICS INC (NASDAQ:LXEO) - ChartMill
Lexeo Therapeutics Price Target Maintained With a $15.00/Share by Leerink Partners - Moomoo
Leerink Partners maintains Outperform rating on Lexeo Therapeutics, $15 price target - TradingView
Lexeo Therapeutics expands position in Friedreich’s ataxia - BioWorld News
Lexeo gains access to Apertura’s gene therapy capsid By Investing.com - Investing.com India
Lexeo Therapeutics, Inc. (LXEO) Stock Price, News, Quote & History - finance.yahoo.com
Lexeo gains access to Apertura’s gene therapy capsid - Investing.com
A gene-delivery tool designed to reach the brain will be available to Lexeo for Friedreich ataxia, a genetic disorder. - Stock Titan
Lexeo Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum - GlobeNewswire
Lexeo to acquire Mantle Therapeutics - The Pharma Letter
Baird reiterates Lexeo Therapeutics stock rating on acquisition deal By Investing.com - Investing.com Australia
Why is Lexeo Therapeutics stock gaining today? By Investing.com - Investing.com Australia
Lexeo Buys Mantle Therapeutics, Inks New Research Deals to Build FA Pipeline - GenomeWeb
Why is Lexeo Therapeutics stock gaining today? - Investing.com
Lexeo stock rises on $21.3M Mantle deal for FA therapies - Investing.com
Raymond James reiterates Strong Buy on Lexeo stock after acquisition By Investing.com - Investing.com Canada
Ericsson, Lexeo Therapeutics And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session - benzinga.com
Lexeo Therapeutics to Acquire Mantle Therapeutics for Up to $21.3 Million - Minichart
Lexeo to acquire Mantle Therapeutics for $21.3M - Investing.com
Lexeo Therapeutics expands FA pipeline with Mantle acquisition - TipRanks
LXEO: Acquisition expands the FA platform with multimodal therapies and up to $21.3M in payments - TradingView
Lexeo to acquire Mantle Therapeutics for $21.3M By Investing.com - Investing.com India
LXEO: Acquisition expands FA treatment platform with new modalities and strategic collaborations - TradingView
Lexeo Therapeutics to Acquire Mantle Therapeutics for $8.3M Upfront, Up to $13M in Milestones - TradingView
Four therapies for a missing brain protein may join Lexeo - Stock Titan
Lexeo Therapeutics Enters Into Agreement To Acquire Mantle Therapeutics And Announces Multiple New Strategic Collaborations To Expand Leadership In Friedreich Ataxia - TradingView
Lexeo Therapeutics, Inc. agreed to acquire Mantle Therapeutics Inc. for $21.3 million . - marketscreener.com
Lexeo Therapeutics at Cantor conference: gene therapy push gains traction By Investing.com - Investing.com Canada
Lexeo Therapeutics to Participate in Upcoming Investor Conferences in September - The Manila Times
Balyasny Asset Management L.P. Expands Stake in Lexeo Therapeuti - GuruFocus
Lexeo Therapeutics (NASDAQ:LXEO) CEO Richard Nolan Townsend Sells 3,345 Shares - MarketBeat
Louis Edward Tamayo Sells 4,117 Shares of Lexeo Therapeutics (NASDAQ:LXEO) Stock - MarketBeat
Lexeo Therapeutics CFO Louis Edward Tamayo Sells 4,117 Shares to Settle RSU Tax Liabilities - Kalkine Media
Lexeo Therapeutics COO Jose Manuel Otero Sells Shares to Cover RSU Tax Liability - Kalkine Media
Lexeo Therapeutics CEO Richard Nolan Townsend Sells 3,345 Shares to Settle RSU Tax Liabilities - Kalkine Media
Lexeo Therapeutics (LXEO) CFO sells shares for RSU taxes - Stock Titan
Lexeo (NASDAQ: LXEO) CEO sale covers RSU tax bill, keeps 374K shares - Stock Titan
Lexeo Therapeutics (LXEO) COO sells 1,304 shares, retains 136K stake - Stock Titan
Lexeo (NASDAQ: LXEO) holder plans stock sale to cover tax bill - Stock Titan
Lexeo Therapeutics (LXEO) holder plans 1,304-share sale - Stock Titan
Lexeo Therapeutics (NASDAQ: LXEO) insider to sell 4,117 shares - Stock Titan
Lexeo Therapeutics (NASDAQ:LXEO) Stock Rating Lowered by Wall Street Zen - MarketBeat
Lexeo Therapeutics (LXEO): OrbiMed entities disclose combined 5% ownership stake - Stock Titan
Lexeo Therapeutics (LXEO): Paradigm BioCapital reports over 5% beneficial stake - Stock Titan
Balyasny Asset Management (LXEO) discloses 7.84M-share Lexeo Therapeutics stake capped at 9.99% - Stock Titan
Lexeo Therapeutics (LXEO): Affinity Asset Advisors reports 8.4% beneficial stake - Stock Titan
Hennion & Walsh Asset Management Inc. Invests $1.24 Million in Lexeo Therapeutics, Inc. $LXEO - MarketBeat
Lexeo Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Lexeo Therapeutics (NASDAQ:LXEO) Announces Earnings Results, Hits Estimates - marketbeat.com
Form 8K Lexeo Therapeutics Inc For: 12 August By Investing.com - Investing.com Nigeria
Lexeo Therapeutics advances gene therapy and gains RMAT status - TipRanks
LXEO: Gene therapies for rare cardiac diseases advance with strong data, pipeline, and financial runway - TradingView
Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights - The Manila Times
Lexeo Therapeutics Announces SUNRISE-FA 2 Trial Initiation for LX2006 and Receives FDA RMAT Designation for LX2020 - Quiver Quantitative
Lexeo Therapeutics, Inc. 2Q 2026: Net loss $25.9M, EPS $(0.30) — 10-Q Summary - TradingView
Lexeo Reports $25.9 Million Q2 Net Loss as SUNRISE-FA 2 Begins - Moomoo
Lexeo Therapeutics (LXEO) narrows loss and ends H1 2026 with $234M cash - Stock Titan
3.06%
2.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):